UHS Q1 2026: Revenue Rises, EPS Advances, and a Tax-Accounting Twist Keeps the Books Subtle

Universal Health Services, Inc. (NYSE: UHS) delivers first-quarter 2026 results, with GAAP and non-GAAP metrics diverging in a way that will likely keep investors parsing the press release for days.

Snapshot: what happened in Q1 2026

Universal Health Services, Inc. reported a solid start to the year, with revenue climbing to $4.495 billion in the three months ended March 31, 2026, up 9.6% from $4.100 billion in the same period of 2025. GAAP net income reached $348.7 million, translating to $5.65 per diluted share. On a non-GAAP basis, adjusted net income was $346.5 million, or $5.62 per diluted share, compared with $319.5 million, or $4.84 per diluted share, in the first quarter of 2025.

Revenue: $4.495 billion (up 9.6% vs Q1 2025)
GAAP net income: $348.7 million; EPS (diluted): $5.65
Adjusted net income: $346.5 million; adjusted EPS: $5.62
Year-ago comparables: net income $316.7 million; EPS $4.80; revenue $4.100 billion

Notes accompany the figures: UHS emphasizes the difference between reported (GAAP) results and its non-GAAP, adjusted results, a standard practice in hospital operators where one-off items and tax nuances frequently steer the accounting narrative.

GAAP vs. non-GAAP: what’s really moving the numbers

The company underscores the role of non-GAAP adjustments and a modest tax benefit in shaping the headline EPS figures. In particular, an after-tax impact of $2.2 million linked to ASU 2016-09, related to improvements in employee share-based payment accounting, contributed to the reported results. This is paired with the usual reminder that adjustments ✱exist✱ to help investors gauge ongoing operating performance, excluding certain non-cash or one-off items, including considerations tied to IRC 162(m) limitations on executive compensation.

For readers tracking EPS, the headline is: GAAP EPS of $5.65 and adjusted EPS of $5.62 signal strength, but the delta between GAAP and non-GAAP remains a reminder that the accounting curtain can obscure the underlying economics in the near term.

There is no explicit EPS consensus or revenue forecast published in the release, which means the market’s read of these numbers will hinge on how investors weigh GAAP fidelity against the company’s non-GAAP narrative and on any implicit guidance that may emerge from management commentary or subsequent calls.

Non-GAAP disclosures and the Supplemental Schedule

UHS points to the Schedule of Non-GAAP Supplemental Information as part of the packet, a common practice intended to provide a more apples-to-apples view of earnings power. For analysts and readers who care about the granularity, this schedule is where you’ll find the numbers that management believes best reflect ongoing performance, separate from the one-off tax accounting and stock-compensation accounting treated under ASU 2016-09.

Context and potential implications for UHS and peers

In a market where hospital operators are juggling payer mix, labor costs, and capital intensity, a 9.6% revenue uptick signals healthy demand and pricing dynamics, at least for the quarter. The 5.62–5.65 range for EPS—GAAP versus adjusted—implies that the core business is generating earnings growth even when you strip out adjustments. The modest tax benefit from ASU 2016-09 is a reminder that corporate tax accounting can tilt the apparent profitability in a given period, even when underlying operations are stable.

For sector peers, the message is twofold. First, non-GAAP disclosures continue to matter, as investors seek a consistent yardstick for operating performance amid tax and stock-compensation accounting effects. Second, a clean top-line growth story—driven by volume, mix, or pricing—remains crucial in a high-capital, labor-intensive industry with sensitivity to payer environments and policy changes.

Analysts and market watchers will likely scrutinize whether the Q1 momentum persists into the next reporting cycle, and how much of the earnings advance is attributable to price, volume, or efficiency gains versus one-time tax effects. In short, UHS’s Q1 2026 results offer a solid data point for EPS growth and revenue progress, but the real question is how durable the drivers are and whether the non-GAAP narrative can coexist with, or perhaps outpace, the GAAP framework in the eyes of investors.

Official color and next steps

The release includes the standard corporate branding and notes the three-month period ended March 31, 2026, issued from King of Prussia, Pennsylvania. For press inquiries, Darren Lehrich, Vice President–Investor Relations, is listed as the contact. As always, the true test for UHS and its peers will be how these numbers translate into revenue visibility, margin resilience, and capital allocation in a sector where the next earnings surprise could hinge on cost control and payer dynamics.